2016 Hematological Malignancies

Points for discussion • IPI=1, aaIPI=1, low risk group • Bulky early stage require full course chemo (not eligible for abbreviated chemo + RT) • CHOP- 14 is superior to CHOP- 21 , the same is not true when Rituximab is added. A large phase 3 randomised study showed that there was no difference between RCHOP-21 and RCHOP-14 (Cunningham, Lancet 2013). • 8 cycles have not been found to be better than 6 cycles (Pfreundschuh, Lancet 2008). • RT for bulky site : most likely site of recurrence. Evidence from German trials. IELSG-37 testing PET-guided RT. • MDM: RCHOPx6 + ISRT with close monitoring of response on PET/CT